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Background
Several ritonavir-boosted PIs (PI/r) are currently recom-
mended for use in first-line therapies for HIV infection.
TDF/FTC and ABC/3TC are widely used with these PI/r,
but there is conflicting evidence on their relative efficacy:
the ACTG 5202 and BICOMBO trials suggest higher effi-
cacy for TDF/FTC, whereas the HEAT trial shows no effi-
cacy difference between the NRTI backbones.
Methods
A systematic MEDLINE search identified 21 treatment
arms in 12 clinical trials of 4,896 antiretroviral naïve
patients, where TDF/FTC (n = 3,340) or ABC/3TC (n =
1,556) was the NRTI backbone used with PI/r. For each
NRTI backbone and PI/r, the percent HIV RNA <50 cop-
ies/mL at week 48 by standardised ITT TLOVR analysis
were combined using inverse-variance weighting. The
effect of baseline HIV-RNA, CD4 count and choice of
NRTI backbone were examined using a weighted analysis
of covariance. Changes in CD4 counts and lipids
(TCHOL, TRIGS, HDL, LDL) were also assessed with the
same methods.
Summary of results
For the TDF/FTC and ABC/3TC groups, there were no sig-
nificant differences in median baseline CD4 (204 and
195, respectively) and mean log10 HIV-RNA (4.9 and 5.0,
respectively). The efficacy of first-line HAART correlated
with baseline HIV-RNA and CD4 count. Use of TDF/FTC
was associated with higher rates of HIV-RNA suppression
in each of the three third agents where data were available
(LPV/r, fAPV/r and ATV/r). (Table 1.)
There was no difference in CD4 change to week 48 by type
of PI or NRTI used. All lipid parameters showed signifi-
cantly greater increases when ABC/3TC was used, vs. TDF/
FTC. TCHOL and TRIGS showed significantly higher
increases for LPV/r and fAPV/r, vs. ATV/r, SQV/r or DRV/r.
Conclusion
This systematic meta-analysis of standardised HIV-RNA
<50 copy efficacy data at week 48, using the FDA TLOVR
algorithm, suggests higher efficacy for first-line use of a
TDF/FTC NRTI backbone, relative to use of ABC/3TC.
However, CD4 increases were similar across the range of
NRTIs and PIs used. Lipid profiles also differed by choice
of NRTI backbone or boosted PI.
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NRTI backbone TDF/FTC ABC/3TC
PI N RNA<50 95% CI N RNA<50 95% CI
LPV/r 2285 74% 72–76% 722 66% 63–70%
fAPV/r 53 75% 63–87% 722 67% 63–70%
ATV/r 493 79% 75–82% 112 77% 68–85%
SQV/r 166 65% 58–72% no data - -
DRV/r 343 84% 80–88% no data - -Page 2 of 2
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